Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

Abstract The incidence of renal cell carcinoma (RCC) is increasing worldwide with an approximate 20% mortality rate. The challenge in RCC is the therapy-resistance. Cancer resistance to treatment employs multiple mechanisms due to cancer heterogeneity with multiple genetic and epigenetic alterations...

Full description

Bibliographic Details
Main Authors: Fengzhi Li, Ieman A. M. Aljahdali, Renyuan Zhang, Kent L. Nastiuk, John J. Krolewski, Xiang Ling
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Renal cell carcinoma (RCC)
Survivin (BIRC5)
Hypoxia inducible factor (HIF)
Nuclear factor erythroid 2-related factor 2 (NRF2)
TP53/p53
AKT
Online Access:https://doi.org/10.1186/s13046-021-02026-1

Internet

https://doi.org/10.1186/s13046-021-02026-1

Similar Items